Clinical trials
Alcoholic Liver Disease clinical trials
Below are recruiting alcoholic liver disease clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06863376RecruitingPhase 2
Carbocisteine for fatty liver disease: safety and benefit study
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
TantaAges 18–65 - NCT06840652Enrolling by invitation
Baclofen for alcohol withdrawal in liver disease
This trial tests if baclofen, a medicine for alcohol dependence, is safe and works for people with chronic liver disease who are actively drinking. It may help you stop drinking alcohol safely.
Sabadell, BarcelonaAges 18–75 - NCT06838468Enrolling by invitation
Study on liver health in alcohol detox patients
This study is looking at liver health in people staying in a detox unit for alcohol use disorder. Researchers want to see how common liver problems are in this group. Participating involves extra tests like blood work, an ultrasound, and a special liver scan (FibroScan).
Sabadell, BarcelonaAges 18–75 - NCT06819917Recruiting
Liver fibrosis test study for fatty liver disease
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
CopenhagenAges 18–75 - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Chandler, ArizonaAges 18–70 - NCT06559878Enrolling by invitation
Liver Mitochondria Study in Fatty Liver Disease
This study looks at how the liver's mitochondria (the energy powerhouses of cells) work in people with fatty liver disease. Participants will have an MRI scan and receive a small amount of fat solution through an IV to see how the liver processes fat.
Helsinki, UusimaaAges 18–75 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT06493799RecruitingPhase 3
Injectable placenta extract for fatty liver disease
This trial tests an injectable medication made from human placenta to see if it can improve liver health in people with fatty liver disease (from alcohol or other causes). It may help lower liver enzyme levels and reduce liver damage.
Yongin-siAges 19–70 - NCT06493773Recruiting
Alcohol help for new liver disease diagnosis
This trial tests a program to help people recently diagnosed with alcohol-related liver disease cut back on drinking. If you qualify, you may get support to improve your liver health.
Køge, KøgeAges 18 years+ - NCT06472973Recruiting
Addiction support after liver transplant
This trial tests a special addiction support program for people who have had a liver transplant because of alcohol-related liver disease. The goal is to help them stay healthy and avoid drinking again.
BesançonAges 18 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06152250Recruiting
Fatty liver inflammation study with liver biopsy
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06355310RecruitingPhase 2
Studying an SGLT2 inhibitor for fatty liver in teens
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
Chicago, IllinoisAges 16–20 - NCT06305624Recruiting
Smartphone app to help people with alcohol-related liver disease stop drinking
This trial tests whether a smartphone program can help people with alcohol-related liver disease reduce or stop drinking. If you have liver disease related to alcohol and have used alcohol in the past 6 months, this app-based support may be for you.
Lansing, MichiganAges 18 years+ - NCT06307964Recruiting
Gut bacteria in alcoholic hepatitis
This trial is looking at bacteria inside the liver of people with alcoholic hepatitis. It may help understand how these bacteria affect the disease and lead to better treatments.
LyonAges 18 years+ - NCT06269510Recruiting
Study to help alcohol-related liver disease patients drink less
This study is testing new ways to help people with alcohol-related liver disease reduce their drinking. Researchers will check if a program offered through your regular liver clinic can help you drink less and stay healthier.
Detroit, MichiganAges 18 years+ - NCT06206616Recruiting
Liver fat in children with celiac disease
This study looks at whether children with celiac disease have fat buildup in the liver. It aims to help doctors understand and manage this condition better.
Palermo, PalermoAges 1–14 - NCT06133101RecruitingPhase 2
Soymilk for liver health in children
This trial tests if drinking soymilk can improve liver health in children who are overweight or have a fatty liver. It compares soymilk to cow's milk to see which is better for reducing liver fat.
Cincinnati, OhioAges 5–16 - NCT06152991Enrolling by invitationPhase 3
Godex for fatty liver: a Phase 3 trial
This study tests an investigational supplement called Godex Carnitine Orotate Complex to see if it helps people with nonalcoholic fatty liver disease (NAFLD) lower their liver enzymes and reduce liver fat. It may be a good option if you have elevated liver enzymes and evidence of fat in your liver.
SeoulAges 19–74 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05733832Recruiting
Transitional care after hospital discharge for serious liver disease
This trial tests an extra support program after you leave the hospital to help people with advanced liver disease avoid complications and stay on track. It may help by providing structured follow-up soon after discharge.
Chicago, IllinoisAges 18 years+ - NCT05890365Recruiting
Study risk of fatty liver in low birth weight adults
This study looks at whether being born with low birth weight is linked to a higher chance of non-alcoholic fatty liver disease (fatty liver not caused by heavy drinking). It compares people born with low birth weight to people born with typical birth weight to better understand risk factors.
HerlevAges 34–49
Hear when a new Alcoholic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcoholic liver disease?
- Yes. Clin2 currently lists 244 recruiting alcoholic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcoholic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcoholic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.